Evidence map›Paper›PMID 40372667›Full record

ArticleDermatology and therapy2025

Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 Trials.

John R Ingram, Jacek C Szepietowski, Lukasz Matusiak, Georgios Kokolakis, Magdalena B Wozniak, Christine-Elke Ortmann, Angela Llobet Martinez, Shoba Ravichandran, Nicolas Thomas, Ivette Alarcon and 4 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03713619 phase3completednot on this map

A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE).

TypeinterventionalSponsorNovartis PharmaceuticalsRan2019 to 2022Enrolled544ConditionsHidradenitis SuppurativaArmssecukinumab, Placebo
NCT03713632 phase3completednot on this map

A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE)

TypeinterventionalSponsorNovartis PharmaceuticalsRan2019 to 2022Enrolled545ConditionsHidradenitis SuppurativaArmsSecukinumab, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

John R IngramDepartment of Dermatology & Academic Wound Healing, Division of Infection and Immunity, Cardiff University, Cardiff, UK. ingramjr@cardiff.ac.uk.ORCID http://orcid.org/0000-0002-5257-1142
Jacek C SzepietowskiDivision of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland.
Lukasz MatusiakDivision of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland.
Georgios KokolakisPsoriasis Research and Treatment Center, Clinic of Dermatology, Venereology, and Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
Magdalena B WozniakNovartis Ireland Limited, Dublin, Ireland.
Christine-Elke OrtmannNovartis Pharma AG, Basel, Switzerland.
Angela Llobet MartinezNovartis Pharma AG, Basel, Switzerland.
Shoba RavichandranNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Nicolas ThomasNovartis Pharma AG, Basel, Switzerland.
Ivette AlarconNovartis Pharma AG, Basel, Switzerland.
Christelle C PieterseSyneos Health, Amsterdam, The Netherlands.
Maryam Shayesteh AlamSimcoMed Health Ltd, 105-5 Quarry Ridge Road, Barrie, ON, L4M 7G1, Canada.
Dimitrios IoannidesFirst Department of Dermatology and Venereology, School of Medicine, Aristotle University School of Medicine, Thessaloniki, Greece.
Alexa B KimballHarvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHidradenitis suppurativa (HS) is a chronic, painful skin disease associated with a high disease burden. Disease-related pain is frequently reported as the most troublesome symptom of HS. The SUNSHINE and SUNRISE phase 3 trials previously reported that secukinumab improved control of pain in patients with moderate to severe HS. The objective of this analysis was to evaluate the impact of secukinumab on multiple aspects of pain in patients with HS from SUNSHINE and SUNRISE.

methodsPatients were randomised to receive secukinumab 300 mg every 2 (SECQ2W) or 4 weeks (SECQ4W), or placebo until week 16. At week 16, the placebo group switched to receive SECQ2W (placebo-SECQ2W) or SECQ4W (placebo-SECQ4W), whereas the secukinumab groups continued their treatment, until week 52. Pain was assessed using the Patient's Global Assessment of skin pain‒at worst on a continuous numeric rating scale (NRS) through week 52. Quartiles were used to categorise pain severity groups based on baseline NRS scores (NRS ≤ 3.3; NRS > 3.3 to ≤ 5.4; NRS > 5.4 to ≤ 7.2; NRS > 7.2). Additional assessments included quality of life (QoL) and pain medication use.

resultsAt week 16, a greater mean (standard deviation) absolute change from baseline in skin pain was observed for patients treated with secukinumab [SECQ2W (- 1.35 (2.16)); SECQ4W (- 1.05 (2.02))] versus placebo [- 0.47 (2.07)]. In the SECQ2W and SECQ4W groups, in patients with NRS > 7.2 at baseline, 20.0% and 12.7% had NRS ≤ 3.3 at week 16, respectively. This improvement in pain was maintained through week 52. Moreover, patients in the NRS ≤ 3.3 category generally experienced better QoL. The proportion of patients reporting pain medication use was generally reduced at weeks 16 and 52 versus baseline in the secukinumab groups.

conclusionThis analysis highlights the sustained benefits of secukinumab in reducing pain in patients with moderate to severe HS. These pain reductions were associated with QoL improvements.

trial registrationClinicalTrials.gov identifier: NCT03713619 (SUNSHINE) and NCT03713632 (SUNRISE).

Indexed as

Acne inversaBiologicsHidradenitis suppurativaHSNRSPainPain controlPain medicationPatient-reported outcomesSecukinumab

Identifiers

PMID40372667
PMCPMC12126416

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.